Phio Pharmaceuticals Corp. News Releases

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Mon, 19 Oct 2026 09:53:00 -0400

Live Presentation and Q&A: Tuesday, October 20, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile Corp. - October 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA therapeutic platform,...

Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance

Tue, 13 Oct 2026 07:00:00 -0400

Critical Manufacturing Milestone Supports Supply Chain Readiness and Planned Phase 2b Clinical Trial Initiation in First Quarter 2027 King of Prussia, Pennsylvania--(Newsfile Corp. - October 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced the successful release of its first commercial-scale cGMP batch of PH-762 drug substance (active...

Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026

Tue, 06 Oct 2026 07:00:00 -0400

Phio invites individual and institutional investors as well as advisors and analysts, to attend online at www.VirtualInvestorConference.comKing of Prussia, Pennsylvania--(Newsfile Corp. - October 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced that Robert Bitterman, President and Chief Executive Officer, will present Phio's INTASYL® siRNA...

Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference

Mon, 05 Oct 2026 07:00:00 -0400

Highlighting its Proprietary INTASYL siRNA Therapeutic Platform and Development Update for Lead PH-762 Program in Cutaneous Squamous Cell Carcinoma King of Prussia, Pennsylvania--(Newsfile Corp. - October 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced that it has accepted the invitation to present at the National Investment Banking...

Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference

Wed, 23 Sep 2026 07:00:00 -0400

Company to Highlight Next Stage of PH-762 Clinical Development in Cutaneous Squamous Cell Carcinoma King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer, today announced that it will present at the Life Sciences Future 2026 Conference, taking place September 30 to October 1, 2026, at the...

Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma

Mon, 14 Sep 2026 07:00:00 -0400

Company Proposes Planned Phase 2b Neoadjuvant Study Following Successful Completion of Phase 1b Trial King of Prussia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that, following the formal completion of the Phase 1b clinical study, it has submitted a meeting request and...

Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Fri, 11 Sep 2026 09:00:00 -0400

Management to Meet with Investors and Highlight Progress and Future Development Plans for PH-762 King of Prussia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing therapeutics based on its proprietary INTASYL® siRNA gene-silencing technology designed to eliminate cancer, today announced that members of its management team will be available for one-on-one investor meetings at the H.C. Wainwright 28th...

Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894

Tue, 11 Aug 2026 07:00:00 -0400

PH-894 protection for chemical structure, genetic sequencing and broad application for proliferative and infectious diseases in U.S. King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing immuno-oncology therapeutics based on its proprietary INTASYL® gene-silencing technology, today announced the receipt of a U.S. Notice of Allowance for a patent covering PH-894, further strengthening the...

Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Thu, 06 Aug 2026 16:05:00 -0400

Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase 1b pharmacology, and new IP announcementsKing of Prussia, Pennsylvania--(Newsfile Corp. - August 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio today reported its financial...

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Wed, 22 Jul 2026 12:30:00 -0400

Live Presentation and Q&A: Tuesday, July 28, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead...